MedTrace Logo

Open Label Transdermal Granisetron to Relieve Chronic Nausea and Emesis

NCT04501211 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2022-02-14

No results posted yet for this study

Summary

To determine the efficacy of open -label transdermal patch on chronic nausea and emesis in patients with gastroparesis

Conditions

Interventions

DRUG

Granisetron

transdermal sancuso patch

Sponsors & Collaborators

  • Kyowa Kirin, Inc.

    collaborator INDUSTRY

  • Indiana University

    lead OTHER

Principal Investigators

  • John M Wo, MD · Indiana University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2020-12-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04501211 on ClinicalTrials.gov